Myopathy Clinical Trials

331 recruitingLast updated: July 25, 2026

There are 331 actively recruiting myopathy clinical trials across 54 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Myopathy Trials at a Glance

331 actively recruiting trials for myopathy are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Not Applicable with 76 trials, with the heaviest enrollment activity in Boston, Houston, and New York. Lead sponsors running myopathy studies include Second Affiliated Hospital, School of Medicine, Zhejiang University, Bristol-Myers Squibb, and China Immunotech (Beijing) Biotechnology Co., Ltd..

Treatments under study

About Myopathy Clinical Trials

Looking for clinical trials for Myopathy? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 331 trials

Recruiting
Phase 1

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled14 locationsNCT07085104
Recruiting
Phase 2

Venous Ethanol for Ventricular Tachycardia

Ventricular TachycardiaIschemic Cardiomyopathy
The Methodist Hospital Research Institute156 enrolled1 locationNCT05511246
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled292 locationsNCT07207811
Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,750 enrolled240 locationsNCT07052903
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled77 locationsNCT06371417
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 2

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

Friedreich AtaxiaCardiomyopathy, Secondary
Lexeo Therapeutics26 enrolled1 locationNCT07721025
Recruiting

Prospective Investigation of Cirrhotic Cardiomyopathy in Humans

Cirrhotic Cardiomyopathy
Vanderbilt University Medical Center440 enrolled2 locationsNCT07658222
Recruiting

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

X-linked Myotubular Myopathy
Astellas Gene Therapies50 enrolled10 locationsNCT06581146
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Phase 1

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

Dilated Cardiomyopathy
AstraZeneca31 enrolled4 locationsNCT07241104
Recruiting
Phase 1Phase 2

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

X-linked Myotubular Myopathy
Astellas Gene Therapies9 enrolled4 locationsNCT07052929
Recruiting
Phase 2

A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

Autosomal Dominant RYR1-Related Myopathy
RyCarma Therapeutics, Inc.28 enrolled9 locationsNCT07560020
Recruiting
Phase 1Phase 2

Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy

Heart FailureDilated Cardiomyopathy (DCM)
Second Affiliated Hospital, School of Medicine, Zhejiang University43 enrolled1 locationNCT06902896
Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

ObesityCardiomyopathyLi-Fraumeni Syndrome+3 more
National Heart, Lung, and Blood Institute (NHLBI)5,000 enrolled3 locationsNCT01143454
Recruiting
Phase 1Phase 2

An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

Dilated Cardiomyopathy (DCM)BAG3 Mutation Associated Dilated Cardiomyopathy
Affinia Therapeutics22 enrolled3 locationsNCT07426419
Recruiting

Hungarian National Systemic Amyloidosis Registry

AL AmyloidosisAmyloid CardiomyopathyATTR Amyloidosis+1 more
Semmelweis University300 enrolled12 locationsNCT07689331
Recruiting
Not Applicable

Effectiveness of a Resilience-Based Rehabilitation Program for Patients With Coronary Heart Disease

Acute Coronary SyndromeTakotsubo CardiomyopathyPsychological resilience
Pensionsversicherungsanstalt130 enrolled1 locationNCT06332859
Recruiting
Not Applicable

Cardiac Contractility Modulation in Chagas Heart Disease

Heart FailureSystolic DysfunctionChagas Cardiomyopathy+2 more
InCor Heart Institute60 enrolled1 locationNCT05519046
Recruiting

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Bayer2,000 enrolled1 locationNCT07235462